Last reviewed · How we verify
HerpV and QS-21
Stimulates the immune system by activating CD4+ T cells through the QS-21 adjuvant
Stimulates the immune system by activating CD4+ T cells through the QS-21 adjuvant Used for Herpes simplex virus 2 (HSV-2) infection.
At a glance
| Generic name | HerpV and QS-21 |
|---|---|
| Also known as | AG-707 |
| Sponsor | Agenus Inc. |
| Drug class | Cancer vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
QS-21 is a saponin adjuvant that enhances the immune response to the HerpV antigen, leading to the activation of CD4+ T cells and the production of antibodies.
Approved indications
- Herpes simplex virus 2 (HSV-2) infection
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HerpV and QS-21 CI brief — competitive landscape report
- HerpV and QS-21 updates RSS · CI watch RSS
- Agenus Inc. portfolio CI